CN115867354B - 具有抗癌活性的化合物 - Google Patents
具有抗癌活性的化合物Info
- Publication number
- CN115867354B CN115867354B CN202180047260.2A CN202180047260A CN115867354B CN 115867354 B CN115867354 B CN 115867354B CN 202180047260 A CN202180047260 A CN 202180047260A CN 115867354 B CN115867354 B CN 115867354B
- Authority
- CN
- China
- Prior art keywords
- compound
- nmr
- pharmaceutical composition
- esi
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047612P | 2020-07-02 | 2020-07-02 | |
| US63/047,612 | 2020-07-02 | ||
| PCT/US2021/040171 WO2022006447A1 (en) | 2020-07-02 | 2021-07-01 | Compounds having anticancer activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115867354A CN115867354A (zh) | 2023-03-28 |
| CN115867354B true CN115867354B (zh) | 2025-08-26 |
Family
ID=79314944
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180047260.2A Active CN115867354B (zh) | 2020-07-02 | 2021-07-01 | 具有抗癌活性的化合物 |
| CN202180047426.0A Active CN116234808B (zh) | 2020-07-02 | 2021-07-01 | 具有抗菌活性的化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180047426.0A Active CN116234808B (zh) | 2020-07-02 | 2021-07-01 | 具有抗菌活性的化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20230295164A1 (https=) |
| EP (2) | EP4175953A4 (https=) |
| JP (2) | JP2023535527A (https=) |
| CN (2) | CN115867354B (https=) |
| AU (2) | AU2021299504A1 (https=) |
| CA (2) | CA3183770A1 (https=) |
| WO (2) | WO2022006432A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11963959B2 (en) * | 2021-08-17 | 2024-04-23 | Southwest Research Institute | Inhibitors for coronavirus |
| WO2024077235A2 (en) * | 2022-10-07 | 2024-04-11 | The Trustees Of Princeton University | Dihydrofolate reductase inhibitors for anti-biotic resistant infections |
| CN118047780A (zh) * | 2022-11-09 | 2024-05-17 | 中国医学科学院药物研究所 | 一类喹唑啉杂环化合物及其抗感染和抗肿瘤的应用 |
| CN119661535B (zh) * | 2023-09-21 | 2026-03-20 | 中国医学科学院药物研究所 | 7H-吡咯并[3,2-f]喹唑啉衍生物及其抗感染应用 |
| WO2025194625A1 (zh) * | 2024-03-22 | 2025-09-25 | 深圳湾实验室坪山生物医药研发转化中心 | 结核病的预防与治疗 |
| WO2025195460A1 (zh) * | 2024-03-22 | 2025-09-25 | 深圳湾实验室坪山生物医药研发转化中心 | 稠环衍生物 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019212933A1 (en) * | 2018-04-30 | 2019-11-07 | Duke University | Compositions and methods for the treatment of senescent tumor cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE45427B1 (en) * | 1976-07-09 | 1982-08-25 | American Home Prod | Pyrrold 3,2if quinazoline-1,3-diamine and related compounds |
| US4118561A (en) * | 1977-04-06 | 1978-10-03 | American Home Products Corporation | 7-(Substituted)-7H-pyrrolo[3,2-f]quinazoline-1,3-diamines |
| JP2005500253A (ja) * | 2001-02-23 | 2005-01-06 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | トロンビン受容体アンタゴニストとしてのアミノメチルピロロキナゾリン化合物 |
| US7253177B2 (en) * | 2004-10-22 | 2007-08-07 | United States Of America As Represented By The Secretary Of The Army | Synthesis and antimalarial activity of pyrrolo[3,2-f]quinazoline-1,3-diamine derivatives |
| US9920058B2 (en) * | 2013-05-06 | 2018-03-20 | Georgia Tech Research Corporation | Molecules with potent DHFR binding affinity and antibacterial activity |
| EP3010923A4 (en) * | 2013-06-20 | 2016-12-14 | Univ Oregon Health & Science | PYRROLOCHINAZOLINVERBINDUNGEN |
| WO2015173802A1 (en) * | 2014-05-11 | 2015-11-19 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Par-1 based therapeutic conjugates and uses thereof |
| US11077109B2 (en) * | 2017-08-01 | 2021-08-03 | The Trustees Of Princeton University | Compounds having antibacterial activity and methods of use |
| CN114514230A (zh) * | 2019-08-20 | 2022-05-17 | 希望之城 | Mettl16抑制剂及其用途 |
-
2021
- 2021-07-01 AU AU2021299504A patent/AU2021299504A1/en active Pending
- 2021-07-01 AU AU2021301264A patent/AU2021301264A1/en active Pending
- 2021-07-01 CA CA3183770A patent/CA3183770A1/en active Pending
- 2021-07-01 JP JP2023524493A patent/JP2023535527A/ja active Pending
- 2021-07-01 EP EP21832744.3A patent/EP4175953A4/en active Pending
- 2021-07-01 US US18/014,032 patent/US20230295164A1/en active Pending
- 2021-07-01 CN CN202180047260.2A patent/CN115867354B/zh active Active
- 2021-07-01 CA CA3183776A patent/CA3183776A1/en active Pending
- 2021-07-01 WO PCT/US2021/040143 patent/WO2022006432A1/en not_active Ceased
- 2021-07-01 CN CN202180047426.0A patent/CN116234808B/zh active Active
- 2021-07-01 US US18/013,302 patent/US20230242540A1/en active Pending
- 2021-07-01 WO PCT/US2021/040171 patent/WO2022006447A1/en not_active Ceased
- 2021-07-01 EP EP21832527.2A patent/EP4175958A4/en active Pending
- 2021-07-01 JP JP2022581398A patent/JP2023532128A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019212933A1 (en) * | 2018-04-30 | 2019-11-07 | Duke University | Compositions and methods for the treatment of senescent tumor cells |
Non-Patent Citations (1)
| Title |
|---|
| A Dual-Mechanism Antibiotic Kills Gram-Negative Bacteria and Avoids Drug Resistance;James K. Martin 等;Cell;20200625;第181卷;1518–1532 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4175958A1 (en) | 2023-05-10 |
| CA3183776A1 (en) | 2022-01-06 |
| JP2023532128A (ja) | 2023-07-26 |
| EP4175953A4 (en) | 2024-08-14 |
| CN116234808A (zh) | 2023-06-06 |
| AU2021301264A1 (en) | 2023-02-02 |
| EP4175953A1 (en) | 2023-05-10 |
| JP2023535527A (ja) | 2023-08-17 |
| US20230295164A1 (en) | 2023-09-21 |
| CN116234808B (zh) | 2025-11-14 |
| EP4175958A4 (en) | 2024-07-17 |
| WO2022006447A1 (en) | 2022-01-06 |
| US20230242540A1 (en) | 2023-08-03 |
| CN115867354A (zh) | 2023-03-28 |
| CA3183770A1 (en) | 2022-01-06 |
| AU2021299504A1 (en) | 2023-02-02 |
| WO2022006432A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN115867354B (zh) | 具有抗癌活性的化合物 | |
| EP3567035B1 (en) | N-substituted 2,5-dioxo-azoline compounds for use in the treatment of cancer | |
| KR20200037876A (ko) | Egfr 및/또는 her2의 저해제 및 사용 방법 | |
| EP2875006B1 (en) | Acid ceramidase inhibitors and their use as medicaments | |
| US20220387345A1 (en) | Anti-cancer compounds acting as non-pgp substrate | |
| US20200181175A1 (en) | Boronic derivatives of hydroxamates as anticancer agents | |
| WO2024074128A1 (en) | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp1) inhibitors and uses thereof | |
| HUP0003148A2 (en) | Cyanoguanidine derivatives, process for producing them and pharmaceutical compositions containing them | |
| KR860001389B1 (ko) | 나트로안식향산 아미드 유도체의 제조방법 | |
| CA2291489A1 (en) | Cyanoguanidines as cell proliferation inhibitors | |
| US20080176923A1 (en) | Proline Derivatives Used as Pharmaceutical Active Ingredients for the Treatment of Tumors | |
| KR20080091134A (ko) | 술린닥의 유도체,이의 용도 및 제조방법 | |
| KR20010013149A (ko) | 세포 증식 억제제로서의 시아노구아니딘 | |
| US20030092637A1 (en) | Novel compounds | |
| JP2025527243A (ja) | 新規なエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ１（ｅｎｐｐ－１）阻害剤およびその使用 | |
| JP2002535338A (ja) | ビス−テルピリジン−白金（ｉｉ）錯体 | |
| EP3596054B1 (en) | 5-carboxamide-2-thiobarbituric acids and use thereof as medicaments | |
| RU2768451C1 (ru) | Селективный антагонист рецепторов типа A2A | |
| RU2068843C1 (ru) | 2-/3-(2-хлорэтил)-3-нитрозоуреидо/-1,3-пропандиол, обладающий противоопухолевой активностью | |
| EP3967684A1 (en) | Antitumoral ascorbic acid esters | |
| HUP0300688A2 (hu) | Bisz[N,N'-bisz(2-halogén-etil)-amino]-foszforamidát-származékok mint daganatellenes hatású hatóanyagok | |
| JPS59501110A (ja) | 抗腫瘍活性を有する薬剤組成物 | |
| US11111219B2 (en) | Polysubstituted pyrimidines inhibiting the formation of prostaglandin E2, a method of production thereof and use thereof | |
| WO2025174721A1 (en) | Vps4 inhibitors | |
| AU2023404558A1 (en) | Benzopyrone compounds as well as preparation method therefor and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |